Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

被引：0
|
作者：
David Schnell
Susanne Buschke
Holger Fuchs
Dietmar Gansser
Rainer-Georg Goeldner
Martina Uttenreuther-Fischer
Peter Stopfer
Sven Wind
Marc Petersen-Sylla
Atef Halabi
Rüdiger Koenen
机构：
[1] Boehringer Ingelheim Pharma GmbH & Co KG,Translational Medicine and Clinical Pharmacology
[2] Boehringer Ingelheim Pharma GmbH & Co KG,Drug Metabolism and Pharmacokinetics
[3] Boehringer Ingelheim Pharma GmbH & Co KG,Global Biometrics and Clinical Applications
[4] Boehringer Ingelheim Pharma GmbH & Co KG,Clinical Development and Medical Affairs
[5] Kiel GmbH,Clinical Research Services (CRS)
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 74卷
关键词：
Afatinib; Hepatic impairment; Pharmacokinetics; Human; Epidermal growth factor receptor (EGFR); Tyrosine kinase inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：267 / 275
页数：8
相关论文
共 50 条
  • [41] Multiple-dose pharmacokinetics and safety of desloratadine in subjects with moderate hepatic impairment
    Gupta, Samir K.
    Kantesaria, Bhavna
    Wang, Zaiqi
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (10): : 1283 - 1291
  • [42] The Pharmacokinetics and Safety Of Idelalisib In Subjects With Moderate Or Severe Hepatic Impairment<bold> </bold>
    Jin, Feng
    Robeson, Michelle
    Zhou, Huafeng
    Hisoire, Grace
    Ramanathan, Srini
    [J]. BLOOD, 2013, 122 (21)
  • [43] Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning
    Nakamaru, Yoshinobu
    Kakubari, Masae
    Yoshida, Kaori
    Akimoto, Makoto
    Todorovic, Vesna
    Greis, Thomas
    Kondo, Kazuoki
    [J]. CLINICAL THERAPEUTICS, 2020, 42 (08) : 1467 - +
  • [44] Pharmacokinetics of Zavegepant Nasal Spray 10 mg in Subjects with Moderate Hepatic Impairment
    Bhardwaj, R.
    Donohue, M.
    Madonia, J.
    Stringfellow, J.
    Morris, B.
    Stock, D.
    Coric, V
    Croop, R.
    Bertz, R.
    [J]. HEADACHE, 2023, 63 : 152 - 152
  • [45] Pharmacokinetics of Zavegepant Nasal Spray 10 mg in Subjects With Moderate Hepatic Impairment
    Bhardwaj, Rajinder
    Donohue, Mary
    Madonia, Jennifer
    Stringfellow, Joseph
    Morris, Beth
    Stock, David A.
    Coric, Vladimir
    Croop, Robert
    Marbury, Thomas C.
    Bertz, Richard
    [J]. CEPHALALGIA, 2022, 42 (1_SUPPL) : 92 - 93
  • [46] Lumiracoxib pharmacokinetics remain unchanged between subjects with moderate degree of hepatic impairment and healthy subjects
    Kalbag, J
    Scott, G
    Yeh, CM
    Gurrieri, P
    Milosavljev, S
    Scott, G
    Rordorf, C
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (09): : 1061 - 1061
  • [47] Pharmacokinetics of escitalopram in subjects with hepatic impairment
    Areberg, J
    Christophersen, JS
    Poulsen, MN
    Larsen, F
    [J]. NORDIC JOURNAL OF PSYCHIATRY, 2005, 59 (05) : 406 - 406
  • [48] Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment
    Marzin, Kristell
    Kretschmar, Gunther
    Luedtke, Doreen
    Kraemer, Sandrine
    Kuelzer, Raimund
    Schlenker-Herceg, Rozsa
    Schmid, Ulrike
    Schnell, David
    Dallinger, Claudia
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (03): : 357 - 363
  • [49] Pharmacokinetics Of Nintedanib In Subjects With Hepatic Impairment
    Marzin, K.
    Kretschmar, G.
    Schlenker-Herceg, R.
    Dallinger, C.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [50] Pharmacokinetics of nelfinavir in subjects with hepatic impairment
    Damle, Bharat
    Hewlett, Dial, Jr.
    Hsyu, Poe-Hirr
    Becker, Mark
    Petersen, Annkatrin
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (11): : 1241 - 1249
12345